bullish
Eisai Pharmaceutical - Plenty at Stake with Anti-Alzheimer R&D Programs but Lenvima Is Key
234 Views20 Feb 2017 13:18
Eisai had high hopes from breast cancer treatment Halaven (eribulin) and epilepsy treatment Fycompa (perampanel). However, neither of the two has...
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 15-minute read)
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- New FDA Draft Rules Ease Approval for Alzheimer's Drugs28 Mar 2018
- Standing Alone in the Ampakines Pipeline: Biogen Sees Potential in Pfizer's Neuropsychiatry Asset15 Mar 2018
- Will Actinogen Ace Alzheimer's?01 Mar 2018
- Eisai Pharmaceutical - Plenty at Stake with Anti-Alzheimer R&D Programs but Lenvima Is Key20 Feb 2017
x